Two new UK studies aim to shed light on the impact of puberty blockers on young people's physical and mental health. The research, part of a wider "Pathways" programme, will investigate the effects of these medications on 226 adolescents aged 10-15 who are being treated in specialist NHS children and young people's gender services.
The studies will compare two groups: those who start taking puberty blockers immediately, and those who wait a year before beginning treatment. Participants' health, wellbeing, and development will be closely monitored over the next 24 months to assess their ongoing care needs, which could include remaining on puberty blockers.
However, not everyone is pleased with the trials. Chay Brown, director of TransActual, has raised concerns that the studies are "coercive in nature" and may cause unnecessary distress for participants who wait an extra year before receiving treatment. He argues that the trials prioritize those who have access to puberty blockers over others, potentially exacerbating existing health disparities.
Professor Emily Simonoff, lead investigator of the new studies, acknowledges that new medications often require clinical trials before being widely available. She notes that the most ethical approach would have been to conduct a trial earlier on, but hopes that this research will contribute to a better understanding of puberty blockers' effects and inform more effective treatment options for young people with gender incongruence.
The results of these studies are expected to be published at least four years from now, providing valuable insights into the impact of puberty blockers on the lives of young people in the UK.
The studies will compare two groups: those who start taking puberty blockers immediately, and those who wait a year before beginning treatment. Participants' health, wellbeing, and development will be closely monitored over the next 24 months to assess their ongoing care needs, which could include remaining on puberty blockers.
However, not everyone is pleased with the trials. Chay Brown, director of TransActual, has raised concerns that the studies are "coercive in nature" and may cause unnecessary distress for participants who wait an extra year before receiving treatment. He argues that the trials prioritize those who have access to puberty blockers over others, potentially exacerbating existing health disparities.
Professor Emily Simonoff, lead investigator of the new studies, acknowledges that new medications often require clinical trials before being widely available. She notes that the most ethical approach would have been to conduct a trial earlier on, but hopes that this research will contribute to a better understanding of puberty blockers' effects and inform more effective treatment options for young people with gender incongruence.
The results of these studies are expected to be published at least four years from now, providing valuable insights into the impact of puberty blockers on the lives of young people in the UK.